![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 20, 2015 11:52:53 AM
1) Prove TIL theory using the P2B including significant improvement in the ability to treat non-responders.
2) Prove that TIL increase is a general capability using the H&N and Breast Cancer studies.
These are open label studies. The final end point results are NOT needed for share price appreciation. There are really only two significant events: first patient enrollment (as it will tell you how long you have to place your bet) and first data readout. If 1 & 2 are shown to be true on the first data readouts then a buyout will happen, and happen quickly. The likely price would be $1B - $3B. If the readout is negative, ONCS will be scrambling to determine how to proceed. Everything else is noise.
My bet is that 1 & 2 work based on the science.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM